Log In
Print
BCIQ
Print
Print this Print this
 

NHS-IL12

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionImmunocytokine composed of 2 IL-12 heterodimers, each fused to one of the H-chains of the NHS76 antibody
Molecular Target
Mechanism of ActionImmunotherapy
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today